多西紫杉醇联合适形放疗治疗老年贲门癌患者的疗效观察  

Weekly Docetaxel and Concomitant Radiotherapy for the Elderly Patients with Unresectable Gastric Cancer

作　　者：张拥军[1] 范久波[2] 李青锋[3] 胡知朋[1] 杨俊波[1] 

机构地区：[1]湖北省襄阳市中心医院胸外科,湖北襄阳441021 [2]湖北省襄阳市中心医院医学检验部,湖北襄阳441021 [3]湖北省襄阳市中心医院肿瘤科,湖北襄阳441021

出　　处：《现代生物医学进展》2012年第3期525-526,510,共3页Progress in Modern Biomedicine

摘　　要：目的:探讨周剂量多西紫杉醇联合三维适形放疗(3DCRT)治疗进展期贲门癌患者的疗效。方法:2007年10月到2009年5月38例不能手术的贲门癌患者行3DCRT,处方剂量62Gy,1.8Gy/次,5次/周;同时联合多西紫杉醇75mg/m2,每周1次,连续6周。用Kaplan-Meier法分析患者的中位无进展生存时间。结果:完全缓解12例,部分缓解18例,30名患者缓解(78.9%),中位无进展生存时间16.4个月。治疗过程中的毒副作用轻,患者可以耐受。结论:周剂量多西紫杉醇化疗联合适形放疗对进展期贲门癌患者是安全、有效的。Objective： To explore the efficacy of weekly docetaxel and concurrent 3DCRT in treatment of elderly patients with unresectable gastric cancer.Methods： During October 2007 to May 2009,38 patients treated with 3DCRT（62 Gy in fractions of 1.8Gy daily,five times weekly） and concurrent docetaxel（75 mg/m2,one time per week for successive six weeks）.The Kaplan-Meier method was used to evaluate the median progression-free survival time.Results： Complete response and partial response were observed in 78.9% of patients.The overall median progression-free survival time was 16.4 months.Toxicities are tolerable.Conclusions： The therapy of 3DCRT plus concomitant chemotherapy based on docetaxel weekly was effective and safe for the treatment of unresectable gastric cancer.

关 键 词：进展期贲门癌 周剂量多西紫杉醇 三维适形放疗 

分 类 号：R735.2[医药卫生—肿瘤]